NEXIEN BIOPHARMA, INC.
company.status.inactiveCIK 1625288fmd_17CQ1854VY5KDYE8X1GDYQ6QMKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2013 to Mar 31, 2025, 46 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Research and development | – | – | – | 0 | 0 | – | 0 | 0 | 0 | 0 |
| Total operating expenses | – | – | – | 1 | 4 | 3 | 2 | 1 | 0 | 0 |
| Operating income | – | – | – | – | – | 8 | 10 | – | – | – |
| Interest expense | 0 | 0 | 0 | – | – | 0 | – | – | – | – |
| Other non-operating income (expense) | – | – | – | – | – | (0) | (0) | (0) | (0) | (0) |
| Net income | (0) | (0) | (0) | (1) | (4) | (3) | (2) | (1) | (0) | (0) |